- The EMA said that European countries can begin to use Pfizer Inc's PFE COVID-19 treatment pill Paxlovid, even though it is not yet authorized in the EU.
- The pill is indicated to treat adults with COVID-19 who do not require supplemental oxygen and are at increased risk of progressing to severe disease.
- Related Link: Final Data Reaffirms Efficacy Of Pfizer's COVID-19 Antiviral Treatment
- The early advice is based on clinical trial data from Pfizer showing 1% of patients (6 out of 607) who took Paxlovid within five days of the start of symptoms were hospitalized within 28 days of starting treatment compared with 6.7% of patients (41 out of 612) given a placebo.
- The FDA has yet to authorize Pfizer's pill.
- Price Action: PFE shares are up 3.71% at $61 during the market session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
